Studies of Elevated Parathyroid Activity - Full Text View

Purpose

Patients whose parathyroid activity is elevated above normal are referred to as having hyperparathyroidism. This study will help researchers better understand the causes of hyperthyroidism and to evaluate and improve methods for diagnosis and treatment.

In this study, patients diagnosed with or suspected of having hyperparathyroidism will be selected to participate. In addition, patients with related conditions such as parathyroid tumors, will also be selected.

Subjects will be asked to provide blood and urine for testing to confirm their condition. They will then be surgically treated by removal of the parathyroid gland(s) (parathyroidectomy).

Subjects with parathyroid tumors will undergo several diagnostic tests to determine the exact location of the tumor as well as the tumor's activity. The tests may include; ultrasounds, nuclear scanning, CT scans, MRI, and specialized blood testing.

Sometimes parathyroidectomy leads to hypoparathyroidism. Options for treating the patients after the surgical procedure will also be addressed. Calcium and Vitamin D supplements are typically the mainstay of post parathyroidectomy therapy. Other potential treatments include transplanting the parathyroid gland(s) to other areas of the body.

Condition

Hyperparathyroidism
Hypocalcemia
Hypoparathyroidism
Parathyroid Neoplasm

MedlinePlus related topics:

Cancer

ChemIDplus related topics:

Parathyroid Calcium gluconate Vitamin D Ergocalciferol

U.S. FDA Resources

Study Type:	Observational

Official Title:	Studies of Hyperparathyroidism and Related Disorders

Further study details as provided by National Institutes of Health Clinical Center (CC):

Study Start Date:

March 1991

Detailed Description:

Patients with confirmed or suspected primary hyperparathyroidism or complications therefrom (such as postoperative hypoparathyroidism) will be admitted for diagnosis and treatment. Patients with moderately severe primary hyperparathyroidism will be treated. The principal diagnostic components are calcium in serum and urine and parathyroid hormone in serum. Treatment will be mainly by parathyroidectomy.

Preoperative testing to localize parathyroid neoplasm(s) will be used usually and with more extended methods in cases with prior neck surgery. Preoperative tumor localization tests will be selected according to clinical indications from the following: ultrasound, technetium-thallium scan, computerized tomography, magnetic resonance imaging, fine needle aspiration for parathyroid hormone assay, arteriogram, selective venous catheterization for parathyroid hormone assay. Options for management of postoperative hypocalcemia include calcium, vitamin D preparations, parathyroid autografts and synthetic parathyroid hormone. Research specimens may consist of blood or tumors.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

INCLUSION CRITERIA:

Patients (male or female any age) with known or suspected primary hyperparathyroidism or a related disorder (such as familial multiple endocrine neoplasia type 1 [FMEN1]) will be evaluated.

The vast majority of patients will be greater than age 18.

In the rare occasion where special resources might be appropriate (uremic patient, young child), the availability of special resources would be confirmed prior to admission.

EXCLUSION CRITERIA:

There are no absolute exclusions.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001277

Contacts


Contact: Patient Recruitment and Public Liaison Office	(800) 411-1222	prpl@mail.cc.nih.gov

Contact: TTY	1-866-411-1010

Locations


United States, Maryland
	United Services University of Health Services	Recruiting
	Bethesda, Maryland, United States, 20889
	National Institutes of Health Clinical Center, 9000 Rockville Pike	Recruiting
	Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

More Information

NIH Clinical Center Detailed Web Page This link exits the ClinicalTrials.gov site

Publications:

Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997 Apr 18;276(5311):404-7.

Chen CC, Skarulis MC, Fraker DL, Alexander R, Marx SJ, Spiegel AM. Technetium-99m-sestamibi imaging before reoperation for primary hyperparathyroidism. J Nucl Med. 1995 Dec;36(12):2186-91.

Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ, Steinmann B, Levi T, Seidman CE, Seidman JG. Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell. 1993 Dec 31;75(7):1297-303.

Study ID Numbers:	910085, 91-DK-0085
First Received:	November 3, 1999
Last Updated:	July 18, 2008
ClinicalTrials.gov Identifier:	NCT00001277
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):

Parathyroid

Calcium

Vitamin D

Study placed in the following topic categories:

Parathyroid Diseases

Hypocalcemia

Metabolic Diseases

Ergocalciferols

Endocrine System Diseases

Parathyroid Neoplasms

Vitamin D

Hyperparathyroidism

Head and Neck Neoplasms

Water-Electrolyte Imbalance

Hypoparathyroidism

Endocrinopathy

Metabolic disorder

Endocrine Gland Neoplasms

Additional relevant MeSH terms:

Calcium Metabolism Disorders

Neoplasms

Neoplasms by Site

ClinicalTrials.gov processed this record on September 05, 2008

Sponsored by:	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT00001277